Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 0.59 |
| ▸ | EGFR | P00533 | 4/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.57 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
| ▸ | STK4 | Q13043 | 1/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | BCR | P11274 | 1/20 | 0.45 |
| ▸ | ABL2 | P42684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459297 | 0.95 | SRC (0.62) | SRCEGFRERBB2ENPP1ABL1 | |
| SCHEMBL6381695 | 0.95 | SRC (0.62) | SRCEGFRERBB2ENPP1ABL1 | |
| SCHEMBL4865201 | 0.89 | EGFR (0.55) | SRCEGFRERBB2STK4 | |
| SCHEMBL13503087 | 0.89 | SRC (0.49) | SRCEGFRERBB2MAP2K1STK4 | |
| SCHEMBL29590073 | 0.85 | SRC (0.62) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL1893090 | 0.85 | SRC (0.62) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL29798697 | 0.84 | SRC (0.45) | SRCEGFRERBB2MAP2K1STK4 | |
| SCHEMBL28557672 | 0.84 | SRC (0.50) | SRCEGFRERBB2STK4 | |
| SCHEMBL1892242 | 0.84 | SRC (0.45) | SRCEGFRERBB2STK4 | |
| SCHEMBL4744821 | 0.84 | EGFR (0.55) | SRCEGFRERBB2STK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
| EP-1263503-B1 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | WYETH CORP (US) | 2005-11-02 | — | — | EP | disclosed |
| CN-1190197-C | Application of cyanoquinoline in preparing medicine for treating or inhibiting colonic polyp | HEWLETT HOLDINGS CORP (US) | 2005-02-23 | — | — | CN | disclosed |
| EP-1117659-B1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | WYETH CORP (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-0973746-B1 | SUBSTITUTED 3-CYANO QUINOLINES | WYETH CORP (US) | 2003-09-24 | — | — | EP | disclosed |
| CN-1121391-C | Substituted 3-cyano quinolines | AMERICAN CYANAMID CO (US) | 2003-09-17 | — | — | CN | disclosed |
| CN-1429126-A | Use of cyanoquinolines for treating or inhibiting colonic polyps | AMERICAN CYANAMID CO (US) | 2003-07-09 | — | — | CN | disclosed |
| EP-1263503-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6384051-B1 | ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2002-05-07 | — | — | US | disclosed |
| WO-2001068186-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
| US-6288082-B1 | COMPOUNDS SUCH AS 6,7-DIETHOXY-4-(INDAN-5-YLAMINO) -QUINOLINE-3-CARBONITRILE USED AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYCSTIC KIDNEY DISEASE | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | disclosed |
| EP-1117659-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | disclosed |
| CN-1259125-A | Substituted 3-cyanoquinolines | AMERICAN CYANAMID CO (US) | 2000-07-05 | — | — | CN | disclosed |
| WO-2000018761-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| EP-0973746-A1 | SUBSTITUTED 3-CYANO QUINOLINES | American Cyanamid Company (US) | 2000-01-26 | — | — | EP | disclosed |
| US-6002008-A | Substituted 3-cyano quinolines | AMERICAN CYANAMID COMPANY | 1999-12-14 | — | — | US | disclosed |
| WO-1998043960-A1 | SUBSTITUTED 3-CYANO QUINOLINES | AMERICAN CYANAMID COMPANY (US) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | SRC 1453/4885EGFR 3929/4885ERBB2 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.